16.43
0.03 (0.18%)
| Penutupan Terdahulu | 16.40 |
| Buka | 16.44 |
| Jumlah Dagangan | 1,886,424 |
| Purata Dagangan (3B) | 1,519,580 |
| Modal Pasaran | 830,475,584 |
| Harga / Jualan (P/S) | 529.13 |
| Harga / Buku (P/B) | 43.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -3.69 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.98% |
| Nisbah Semasa (MRQ) | 10.44 |
| Aliran Tunai Operasi (OCF TTM) | -127.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.82 M |
| Pulangan Atas Aset (ROA TTM) | -58.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | KalVista Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.40 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.47% |
| % Dimiliki oleh Institusi | 112.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 6,728,985 |
| Tang Capital Management Llc | 30 Sep 2025 | 5,041,798 |
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 5,039,867 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 4,768,712 |
| Parkman Healthcare Partners Llc | 30 Sep 2025 | 1,735,003 |
| Silverarc Capital Management, Llc | 30 Sep 2025 | 1,363,378 |
| Octagon Capital Advisors Lp | 30 Sep 2025 | 1,273,333 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (Needham, 70.42%) | Beli |
| 28.00 (Citizens, 70.42%) | Beli | |
| 28.00 (JMP Securities, 70.42%) | Beli | |
| Median | 28.00 (70.42%) | |
| Purata | 28.00 (70.42%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 13.96 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 04 Dec 2025 | 28.00 (70.42%) | Beli | 16.40 |
| 12 Sep 2025 | 28.00 (70.42%) | Beli | 14.01 | |
| Citizens | 11 Nov 2025 | 28.00 (70.42%) | Beli | 11.47 |
| JMP Securities | 12 Sep 2025 | 28.00 (70.42%) | Beli | 14.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AUDHYA PAUL K. | - | 13.36 | -5,296 | -70,755 |
| PALLEIKO BENJAMIN L | - | 13.36 | -10,940 | -146,158 |
| PIEKOS BRIAN | - | 13.36 | -4,471 | -59,733 |
| YEA CHRISTOPHER | - | 13.36 | -4,331 | -57,862 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,038 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -334,508 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 13.36 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PALLEIKO BENJAMIN L | Pegawai | 24 Nov 2025 | Jual (-) | 10,940 | 13.36 | 146,158 |
| AUDHYA PAUL K. | Pegawai | 24 Nov 2025 | Jual (-) | 5,296 | 13.36 | 70,755 |
| YEA CHRISTOPHER | Pegawai | 24 Nov 2025 | Jual (-) | 4,331 | 13.36 | 57,862 |
| PIEKOS BRIAN | Pegawai | 24 Nov 2025 | Jual (-) | 4,471 | 13.36 | 59,733 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |